Kyntra Bio posts Q3 profit and cuts royalty payments while seeking Phase 3 funding
Kyntra Bio reported third‑quarter 2026 net income of $0.2 million, or $0.04 per share, reversing a $13.1 million loss a year earlier. Revenue was $1.8 million. The company restructured its royalty financing agreement, lowering the maximum royalty obligation to $15 million and cutting the cap from $125 million to $65 million, and said it expects more than $20 million of operating‑expense savings. The planned Phase 3 roxadustat trial for LR‑MDS patients will proceed only if a strategic partnership or external capital raise is secured.
Why it matters
The royalty reduction and projected expense savings improve cash runway, extending it into 2028 per the filing. However, the Phase 3 trial’s funding uncertainty creates execution risk for the company’s lead product.
Key facts
- 1Q3 2026 net income was $0.2 million, or $0.04 per share. quantisnow.com
- 2Q3 2026 revenue was $1.8 million. quantisnow.com
- 3Cash and receivables at September 30, 2026 totaled $44.1 million. quantisnow.com
- 4Maximum royalty payments were reduced from $125 million to $65 million, leaving a remaining cap of $15 million. quantisnow.com
- 5The company expects operating‑expense savings of over $20 million in 2027 and 2028. quantisnow.com
- 6The Phase 3 roxadustat trial is planned for 1Q 2027 and depends on securing a partnership or external capital raise. quantisnow.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.